Contributions
Abstract: P993
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Exosomes are extracellular nanoparticles, sized 30-100 nm, produced by a warity of celltypes. They have been found, in human, in all body fluids. Their biological function is largely unknown. In oncology, a potential role in metastasis formation has been suggested. These nanoparticles display surface antigens and contain proteins and genetic material. They have the potential, to play a role in many biological and pathological processes.
Objective: To investigate the role of exosomal nanoparticles in MS pathology. Evaluate exosomes as potential players in the immunopathogenesis of MS and as potential biomarkers of tissue destruction and nerve cell damage.
Methods: Ten patients with newly diagnosed relapsing remitting MS and 11 age and gender matched healthy controls (HC) were prospectively investigated. They all underwent blood sampling and spinal tap by the same standard procedure. The exosomes were enriched from 9,5 ml cerebrospinal fluid (CSF) and 7 ml serum by escalating centrifugation, encompassing two runs, each of 1 h at 100000 G, with wash in between. The concentration of exosomes was verified by Nanodrop and particle size by Zetaview. Exosome specific antigens (CD9 and CD 63) were verified by FACS analysis. Electron microscopy from one sample visualized exosomes.
Results: In serum, exosomes were found in all samples. In CSF, exoxomes were found in 9 patients and in 5 controls. MS patients had higher concentrations of exosomes in CSF (mean 0,71 µg/ml vs 0,24 µg/ml (p=0,016). However, no difference was found in the concentration of exosomes in serum. The concentration of exosomes did not correlate with lymphocyte count in CSF, presence of contrast enhancing lesions on MRI or Neurofilament light (marker of axonal damage) in CSF.
Discussion: Exosomes are detectable in CSF and serum. Higher concentrations of exosomes are found in CSF of MS patients compared to HC. Exosomes might participate in the pathophysiology of MS, but we found no association with other disease activity associated biomarkers. We will proceed by exploring unique surface structures and the content of exosomes.
Disclosure: MA has received compensation for lectures and/oradvisory boards from Biogen, Genzyme, and Novartis. VL Nothing to disclose
LN Nothing to disclose
CM has received honoraria for lectures and advisory boards from Biogen
and Novartis
JLhas received travel support and/or lecture honoraria from Biogen, Novartis, Teva, Almirall, and Genzyme/Sanofi Aventis for Almirall, Teva, Biogen, Novartis, and Genzyme/SanofiAventis; has served on scientific advisory boards
ET Nothing to disclose
Abstract: P993
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Exosomes are extracellular nanoparticles, sized 30-100 nm, produced by a warity of celltypes. They have been found, in human, in all body fluids. Their biological function is largely unknown. In oncology, a potential role in metastasis formation has been suggested. These nanoparticles display surface antigens and contain proteins and genetic material. They have the potential, to play a role in many biological and pathological processes.
Objective: To investigate the role of exosomal nanoparticles in MS pathology. Evaluate exosomes as potential players in the immunopathogenesis of MS and as potential biomarkers of tissue destruction and nerve cell damage.
Methods: Ten patients with newly diagnosed relapsing remitting MS and 11 age and gender matched healthy controls (HC) were prospectively investigated. They all underwent blood sampling and spinal tap by the same standard procedure. The exosomes were enriched from 9,5 ml cerebrospinal fluid (CSF) and 7 ml serum by escalating centrifugation, encompassing two runs, each of 1 h at 100000 G, with wash in between. The concentration of exosomes was verified by Nanodrop and particle size by Zetaview. Exosome specific antigens (CD9 and CD 63) were verified by FACS analysis. Electron microscopy from one sample visualized exosomes.
Results: In serum, exosomes were found in all samples. In CSF, exoxomes were found in 9 patients and in 5 controls. MS patients had higher concentrations of exosomes in CSF (mean 0,71 µg/ml vs 0,24 µg/ml (p=0,016). However, no difference was found in the concentration of exosomes in serum. The concentration of exosomes did not correlate with lymphocyte count in CSF, presence of contrast enhancing lesions on MRI or Neurofilament light (marker of axonal damage) in CSF.
Discussion: Exosomes are detectable in CSF and serum. Higher concentrations of exosomes are found in CSF of MS patients compared to HC. Exosomes might participate in the pathophysiology of MS, but we found no association with other disease activity associated biomarkers. We will proceed by exploring unique surface structures and the content of exosomes.
Disclosure: MA has received compensation for lectures and/oradvisory boards from Biogen, Genzyme, and Novartis. VL Nothing to disclose
LN Nothing to disclose
CM has received honoraria for lectures and advisory boards from Biogen
and Novartis
JLhas received travel support and/or lecture honoraria from Biogen, Novartis, Teva, Almirall, and Genzyme/Sanofi Aventis for Almirall, Teva, Biogen, Novartis, and Genzyme/SanofiAventis; has served on scientific advisory boards
ET Nothing to disclose